Alkermes (NASDAQ:ALKS – Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, February 15th. Analysts expect Alkermes to post earnings of $0.43 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Alkermes Stock Up 4.4 %
Shares of Alkermes stock opened at $28.52 on Tuesday. Alkermes has a 1 year low of $22.01 and a 1 year high of $33.71. The business has a 50-day moving average of $27.62 and a two-hundred day moving average of $27.31. The company has a market capitalization of $4.76 billion, a P/E ratio of 23.00 and a beta of 0.55. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.91 and a quick ratio of 2.53.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the company. Evercore ISI upgraded Alkermes from an “in-line” rating to an “outperform” rating in a report on Tuesday, October 24th. Bank of America raised their price target on shares of Alkermes from $27.00 to $29.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 2nd. StockNews.com lowered shares of Alkermes from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 5th. Mizuho decreased their target price on shares of Alkermes from $37.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday, October 26th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $33.00 price target on shares of Alkermes in a research report on Monday, November 20th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.43.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Corient Private Wealth LLC bought a new stake in shares of Alkermes in the 4th quarter valued at about $259,000. Creative Planning raised its stake in Alkermes by 29.2% in the third quarter. Creative Planning now owns 10,023 shares of the company’s stock valued at $281,000 after buying an additional 2,266 shares during the period. Morgan Stanley lifted its position in shares of Alkermes by 79.5% in the third quarter. Morgan Stanley now owns 2,012,792 shares of the company’s stock valued at $56,378,000 after buying an additional 891,641 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Alkermes by 67.1% in the third quarter. The Manufacturers Life Insurance Company now owns 112,830 shares of the company’s stock valued at $3,160,000 after buying an additional 45,298 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Alkermes by 31.1% during the 3rd quarter. Royal Bank of Canada now owns 27,573 shares of the company’s stock worth $772,000 after acquiring an additional 6,547 shares during the period. Institutional investors own 95.21% of the company’s stock.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer.
- Five stocks we like better than Alkermes
- What is a Secondary Public Offering? What Investors Need to Know
- 3 attractive stocks that insiders are buying
- What is the FTSE 100 index?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What is a Special Dividend?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.